Retatrutide Suppliers: How the Best Sources Compare

Retatrutide suppliers separate on four checkable things: whether the certificate of analysis is batch-specific, whether purity is a figure tied to a named method rather than an adjective, whether vial content is stated in milligrams on the listing itself, and whether the published price normalizes to a defensible cost per milligram. On that last point the arithmetic is short — a 10 mg vial listed at $100 is $10.00/mg, and a 20 mg vial at $195 is $9.75/mg (HEEZ Research catalog, prices as of September 2026). Everything else on a listing page is either one of those four facts in different clothing, or decoration.

What does retatrutide cost per milligram across vial sizes?

Vial prices are not comparable across suppliers until they are divided by milligram content. The formula is price ÷ mg = cost per mg.

Vial size (mg)	Listed price (USD)	Arithmetic	Cost per mg (USD)
10	100	100 ÷ 10	10.00
20	195	195 ÷ 20	9.75

Cost per milligram computed from HEEZ Research catalog retatrutide listings, prices as of September 2026. Division shown in the third column.

The larger vial is 2.5% cheaper per milligram: $10.00 − $9.75 = $0.25, and $0.25 ÷ $10.00 = 2.5%. Put another way, buying two 10 mg vials costs $200 against $195 for a single 20 mg vial, a $5 difference for the same 20 mg of material.

That 2.5% gap is small, which is the useful finding. A supplier whose larger vial is dramatically cheaper per milligram than its own small vial is telling you something about how it prices, and a supplier whose larger vial is more expensive per milligram has either a pricing error or a reason it should state. Either way, run the division before comparing two sellers, because sticker price alone ranks vials by size rather than by value.

Which seven checks actually separate one supplier from another?

These are ordered by how much information each one adds, and each is falsifiable from the listing page and the COA alone.

1. The COA is batch-specific and the lot number on it matches the lot printed on the vial. A generic PDF with no lot reference documents the supplier’s template, not your vial.
2. Purity is a percentage tied to a named method — HPLC, typically — not “high purity” or “pharmaceutical grade.” Compare the reported figure across suppliers rather than against a threshold you invented.
3. Identity is confirmed separately from purity. Mass spectrometry answers “is this the right molecule”; HPLC answers “how much of the sample is one peak.” A listing that shows only one of the two has documented half the question. Suppliers that publish both are also the ones most likely to hold batch-to-batch COA consistency across orders.
4. Vial content is stated in milligrams per vial, with the lyophilized state made explicit. Ambiguity between “10 mg” as total content and “10 mg” as a post-reconstitution concentration breaks every price comparison downstream.
5. Size and price are both visible without an account. Comparing per-milligram cost only works when both numbers sit on the same public page; this retatrutide suppliers listing publishes both vial sizes with both prices, which is what makes the division in the table above possible at all.
6. The COA carries a test date and a retest or reanalysis date, plus stated storage conditions. A test date with no retest interval leaves the shelf-life question open.
7. The testing lab is named and the name resolves. An independent lab you can look up is a different claim from “third-party tested” with no party named.

Checks 1 through 3 are the ones that actually reorder a supplier list. Checks 4 through 7 are cheap to verify and expensive to fake, so a supplier failing them is usually failing the first three as well.

Why does vial size change the concentration math?

Two vials with identical purity produce different concentrations at the same reconstitution volume, which is why “milligrams per vial” has to be read alongside the volume a listing suggests.

Take a 10 mg vial with 2 mL of bacteriostatic water: 10 mg ÷ 2 mL = 5 mg/mL. A U-100 insulin syringe holds 100 units per mL, so 5 mg ÷ 100 units = 0.05 mg per unit, and 0.05 mg × 1000 = 50 mcg per unit.

The same 2 mL into a 20 mg vial gives 20 mg ÷ 2 mL = 10 mg/mL, which is 0.1 mg, or 100 mcg, per unit — double the first figure at the identical mark on the syringe. Checking the first result backward: 100 units × 0.05 mg = 5 mg, which is the 5 mg/mL the division produced.

The practical consequence for comparing retatrutide suppliers is that a listing quoting a concentration without stating the reconstitution volume it assumes has published a number that cannot be checked. Ask for milligrams per vial; derive the concentration yourself.

What does the published trial literature say about the specs worth checking?

Retatrutide’s dose range in published research is the reason vial sizing matters at all. The phase 2 obesity trial reported in the 2023 NEJM triple-hormone-receptor agonist retatrutide report enrolled 338 adults, randomized them to once-weekly subcutaneous retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg (or placebo) for 48 weeks, with percentage change in body weight from baseline to 24 weeks as the primary endpoint.

Weekly dose arm	Least-squares mean weight change at 24 weeks	Source
Placebo	−1.6%	NEJM phase 2, n=338
1 mg	−7.2%	NEJM phase 2, n=338
4 mg (combined)	−12.9%	NEJM phase 2, n=338
8 mg (combined)	−17.3%	NEJM phase 2, n=338
12 mg	−17.5%	NEJM phase 2, n=338

Primary-endpoint figures at 24 weeks from the phase 2 obesity trial linked above. At 48 weeks the same trial reported −8.7% in the 1 mg group and −17.1% in the combined 4 mg group.

Two things follow for sourcing. First, the studied dose steps span a twelvefold range (12 mg ÷ 1 mg = 12), so a supplier offering only one vial size is offering less granularity than the literature works in. Second, the program has moved into registrational scale: the TRIUMPH phase 3 program design paper describes four multicenter, randomized, double-blind studies of weekly subcutaneous retatrutide against placebo in over 5,800 participants, covering weight management, obstructive sleep apnea, and knee osteoarthritis. Compounds under active registrational study attract more listings, and more listings means more variance in documentation quality, not less. Material sold on these listings is for research use only.

What should you check before placing a repeat order?

The comparison changes once you are ordering a second time, because you now have a baseline. Pull the previous COA and set it beside the new one: same lab, same method, purity figure within a range you would call consistent, and a lot number that differs from the last one. A repeat lot number on a “new” batch is a documentation problem regardless of what the purity figure says.

Terms shift between the first and second order too, which is why minimum order quantity terms and per-order pricing tiers are worth re-reading rather than assumed carried over. If a supplier’s per-milligram cost has moved since your last purchase, redo the price ÷ mg division rather than trusting the ranking you built the first time.

If the second COA does not hold up, the fastest recovery is not a fresh search but a return to the shortlist you already built, which is the argument for deciding early how many listings to compare and keeping the rejected ones on file with their documentation. Where a shortlist rests partly on customer feedback, apply the same skepticism you would to a purity claim, since vetting supplier reviews is subject to the same fabrication pressure as a COA template.

Record two fields at every purchase: the lot number and the reported purity figure with its method. Those two values are what make the next COA comparable, and no supplier will keep that record for you.